CABALETTA BIO, INC. (CABA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -80.94×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | -80.94× | Operating income ÷ reported interest expense. $-185.52M ÷ $2.29M ≈ -80.94× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 157.80M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 20.83M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -185.52M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 2.29M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $157.80M | (m) | $20.83M | $-185.52M | $2.29M | (m) | (m) | -80.94× | Reported |
| 2026-03-31 | $151.01M | (m) | $21.03M | $-179.40M | $2.35M | (m) | (m) | -76.47× | Reported |
| 2025-12-31 | $142.67M | (m) | $20.94M | $-172.24M | $2.00M | (m) | (m) | -85.95× | Reported |
| 2025-09-30 | $132.01M | (m) | $22.09M | $-163.41M | $2.20M | (m) | (m) | -74.38× | Reported |
| 2025-06-30 | $118.48M | (m) | $21.53M | $-149.87M | $1.61M | (m) | (m) | -92.92× | Reported |
| 2025-03-31 | $104.27M | (m) | $20.84M | $-134.25M | $1.04M | (m) | (m) | -128.83× | Reported |
| 2024-12-31 | $97.20M | (m) | $19.46M | $-125.14M | $748.00K | (m) | (m) | -167.30× | Reported |
| 2024-09-30 | $89.08M | (m) | $17.11M | $-114.50M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $76.57M | (m) | $14.86M | $-100.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $64.94M | (m) | $12.65M | $-85.73M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $55.42M | (m) | $11.34M | $-74.66M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $50.42M | (m) | $9.87M | $-67.82M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $44.85M | (m) | $8.59M | $-60.93M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $42.56M | (m) | $7.57M | $-58.10M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $39.30M | (m) | $6.90M | $-54.14M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $36.82M | (m) | $6.92M | $-51.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $36.77M | (m) | $6.70M | $-51.52M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $35.11M | (m) | $6.30M | $-49.60M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $32.49M | (m) | $5.80M | $-46.31M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $28.35M | (m) | $5.52M | $-41.75M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $25.83M | (m) | $5.14M | $-38.60M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $23.31M | (m) | $4.83M | $-35.65M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $21.38M | (m) | $4.39M | $-33.83M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $18.63M | (m) | $3.89M | $-30.36M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $16.20M | (m) | $3.33M | $-26.98M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $13.53M | (m) | $2.68M | $-22.59M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $11.67M | (m) | $2.30M | $-18.68M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.47M | (m) | $606.00K | $-6.19M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |